Citigroup Inc Zymeworks Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$4.65 - $7.43 $2,627 - $4,197	-565 Reduced 92.17%	48 $0
Q2 2022 Aug 10, 2022	SELL	$4.82 - $7.7 $4,154 - $6,637	-862 Reduced 58.44%	613 $3,000
Q1 2022 May 12, 2022	BUY	$6.0 - $16.98 $3,990 - $11,291	665 Added 82.1%	1,475 $10,000
Q4 2021 Feb 10, 2022	BUY	$15.19 - $29.33 $1,184 - $2,287	78 Added 10.66%	810 $13,000
Q3 2021 Nov 10, 2021	BUY	$27.35 - $37.28 $20,020 - $27,288	732 New	732 $22,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $949M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.